SNAI2 and central nervous system cancer: We used certain TMZ concentrations to treat these glioma cells (U87‐EGFRvIII 500 μM/72 h, GSC464 200 μM/72 h, SNB19 100 μM/72 h, and GSC267 100 μM/72 h, based on the IC50 of temozolomide); the results of the CCK‐8 assay showed that overexpression of Slug prevented the IFI30 knockdown‐induced enhancement of the efficacy of TMZ and increased the cell survival rate.